Gilead Sciences, Inc. - Feb 12, 2024 Form 4 Insider Report for Kyverna Therapeutics, Inc. (KYTX)

Role
10%+ Owner
Signature
Gilead Sciences, Inc. By: /s/ Andrew D. Dickinson
Stock symbol
KYTX
Transactions as of
Feb 12, 2024
Transactions value $
$20,020,000
Form type
4
Date filed
2/13/2024, 05:48 PM
Previous filing
Feb 7, 2024
Next filing
Apr 3, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KYTX Common Stock Conversion of derivative security +3.22M 3.22M Feb 12, 2024 Direct F1, F2
transaction KYTX Common Stock Purchase $20M +910K +28.29% $22.00* 4.13M Feb 12, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KYTX Series A-2 Convertible Preferred Stock Conversion of derivative security $0 -6.89M -100% $0.00* 0 Feb 12, 2024 Common Stock 1.51M Direct F1, F2
transaction KYTX Series B Convertible Preferred Stock Conversion of derivative security $0 -7.75M -100% $0.00* 0 Feb 12, 2024 Common Stock 1.7M Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Gilead Sciences, Inc. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The Series A-2 Convertible Preferred Stock and the Series B Convertible Preferred Stock converted into Kyverna Therapeutics, Inc. common stock on a 4.5511-for-1 basis and had no expiration date.
F2 Reflects a 1-for-4.5511 reverse stock split, which became effective on January 30, 2024.